Abstract
The purpose of this study was to determine the percentage of treatment-naïve glaucoma patients initially treated with latanoprost monotherapy who do not respond with a clinically meaningful reduction of intraocular pressure (IOP). A database search of previously untreated patients with newly diagnosed primary open angle glaucoma, ocular hypertension or pseudoexfoliative glaucoma initially treated with once-daily latanoprost, 0.005% monotherapy was conducted. Charts were randomly reviewed until 20 patients meeting inclusion criteria were identified. Baseline IOP was compared to IOP measured 1 to 3 months after the initiation of therapy. Intraocular pressure (±S.D.) following latanoprost treatment (17.0 ± 3.5 mm Hg) was significantly (p < 0.0005) less than baseline (23.9 ± 4.2 mm Hg) in the study population. Based on our criteria of a clinically meaningful decrease in IOP, we identified a subgroup of patients (25%) who were non-responsive to latanoprost monotherapy. Non-responders did not differ from responders with regard to baseline IOP or age. Although latanoprost may be an effective IOP-lowering agent in most patients, there exists a subgroup of patients who are unresponsive. As with any topical glaucoma agent, IOP must be monitored regularly to confirm effectiveness.
Get full access to this article
View all access options for this article.